徐必学，男，理学博士，研究员，博士生/硕士生导师（学术型/专业型）。2009年3月至2012年9月，国家公派留学法国索邦大学（原巴黎第六大学），获理学博士学位。2014年第六届“贵州省优秀科技工作者”，2015年“贵州省第十批优秀青年科技人才”；2016年贵州省第三批“百”层次创新型人才。主持国家自然科学基金3项、省部级科研项目6项。作为主要参与人完成已结题的国家级项目6项、省部级项目10项、横向课题5项。已发表论文90多篇，其中SCI论文35篇。申请获得授权的中国发明专利10件、申请获得授权的美国发明专利1件（第二发明人），已完成2件授权专利的转让实施。作为项目主要参与人，完成了治疗乙肝化药1.1类新药“替芬泰”的发现及其临床前研究工作并获得了国家食品药品监督管理总局颁发的临床试验批件。国家科技专家库、贵州、河北、广西、江西、山东等省和西藏自治区的科技专家库专家；《中国药学杂志》《合成化学》和《中南药学》编委；《European Journal of Medicinal Chemistry》、《Bioorganic Chemistry》、《Journal of Molecular Structure》《Bioorganic & Medicinal Chemistry》《Current Organic Chemistry》、《Journal of Carbohydrate Chemistry》、《Molecular Diversity》、《中国药学杂志》等期刊审稿专家。指导已毕业的硕士/博士研究生37名。其中有3名硕士毕业生获得国家留学基金委全额奖学金资助出国留学攻读博士学位。

联系方式：bixue_xu@126.com

主要研究方向：药物合成、靶向药物设计、基于中药民族药的创新药物研究。

代表性科研项目：

（1）国家自然科学基金，靶向Werner解旋酶的氟代喹唑啉衍生物设计、合成及其抗白血病活性研究，82260675，在研，主持；

（2）贵州省科技计划项目，肿痛舒喷雾剂工艺与质量标准提升研究，黔科合人才KJFZ〔2025〕017，在研，主持；

（3）国家自然科学基金，马蹄金素氟代二肽模拟物的设计合成及抗HBV活性研究，81760623，已结题，主持；

（4）国家自然科学基金，肝靶向马蹄金素衍生物的设计、合成、抗乙肝病毒活性及作用机制研究，81360472，已结题，主持；

（5）贵州省科技计划项目，中药民族药功效与利用研究平台及创新能力建设，已结题，黔科中引地[2022]4015，已结题，主持；

（6）贵州省科技计划项目，贵州省高层次创新型人才，黔科合平台人才【2016】5678，已结题，主持；

（7）贵州省优秀青年科技人才培养对象专项，具有抗糖尿病活性的黄酮糖苷类化合物

设计、合成及活性研究，黔科合人字（2015）24号，已结题，主持；

（8）中国科学院“西部之光”人才计划项目，苯丙氨酸二肽衍生物的抗白血病活性及机制研究，已结题，主持。

代表性SCI论文：

[1] Zhiqiong Luo^#, Guangcan Xu^#, Cheng Li , Zhilu Sun, Haonan Chen, Mingyue Yang, Yi Ye, Qianyu Chen, Bixue Xu*, Heng Luo*, Baofei Sun*. Hijacking the Hydrogen Sulfide Axis: A Novel 4-Trifluoromethylquinoline Derivative Suppresses Glioblastoma via Cystathionine γ-Lyase Suppression[J]. Journal of Medicinal Chemistry, 2026, 69(3): 3457-3476.(IF 6.8).

[2] Mengsha Mao^#, Liangliang Hu^#, Xiangkai Kong, Shijiao Wei, Ping Yi, Gang Yu, Guangcan Xu, Jia Yu, Sha Cheng, Xiaoping Zeng, Kun Liu, Bixue Xu*, Heng Luo*, Xueling Meng*. Novel trifluoromethylquinoline derivatives as potent tubulin polymerization inhibitors with antitumor activity[J]. Bioorganic & Medicinal Chemistry. 2026, 132: 118472.(IF3.0).

[3] Gang Yu#, Jia Yu#, Yunyun Zhou, Kun Liu, Xiaolin Peng, Guangcan Xu, Chao Chen, Xueling Meng, Xiaoping Zeng, Hui Wu, Ningning Zan, Heng Luo*, Bixue Xu*. Discovery of novel quinazoline derivatives containing trifluoromethyl against cell proliferation by targeting werner helicase[J]. Molecular diversity. 2026, 30(1): 423-445.(IF3.8).

[4] Cheng Li^#, Sha Cheng^#, Jia Yu, Qian Zheng, Gang Yu, Mei Xu, Xueling Meng, Xiaoping Zeng, Kun Liu, Bixue Xu*, Heng Luo*, Guangcan Xu*. Hit to lead optimization of the 4-trifluoromethylquinoline derivatives as novel SGK1 inhibitors with potent anti-prostate cancer activity[J]. European journal of medicinal chemistry. 2025, 287, 117336.(IF6.0).

[5] Xinyu Liu^#, Shijiao Wei^#, Gang Yu, Ping Yi, Wei Tu, Yafang Zhou, Jia Yu, Xuelin Meng, Yunyun Zhou, Bixue Xu*, Heng Luo*, Guangcan Xu*. Discovery of novel 2,6-disubstituted-3-cyano-4-(trifluoromethyl)pyridine derivatives as potential anti‑prostate cancer agents targeting BLM helicase[J]. Journal of Molecular Structure. 2025, 1343, 142837.( IF4.7).

[6] Huimin Li^#, Jia Yu^#, Gang Yu, Sha Cheng, Hui Wu, Jiaomei Wei, Chang You, Kun Liu, Menghan Wang, Xueling Meng, Guangcan Xu*, Heng Luo*, Bixue Xu*. Design and synthesis of N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as potential Werner-dependent antiproliferative agents [J]. Molecular Diversity. 2025, 29(1): 195-214.(IF3.8).

[7] Guangcan Xu^#, Lanlan Li^#, Mengfan Lv, Cheng Li, Jia Yu, Xiaoping Zeng, Xueling Meng, Gang Yu, Kun Liu, Sha Cheng, Heng Luo*, Bixue Xu*. Discovery of novel 4-trifluoromethyl-2-anilinoquinoline derivatives as potential anti-cancer agents targeting SGK1 [J]. Molecular Diversity. 2025, 29(3): 1945-1965. (IF3.8).

[8] Menghan Wang^#, Jia Yu^#, Xinyi Huang, Gang Yu, Qi Liang, Sha Cheng, Xueling Meng, Guangcan Xu, Huimin Li, Heng Luo*, Bixue Xu*. Design, synthesis and antitumor activity of 2-substituted quinazoline-4-amine derivatives [J]. Bioorganic & Medicinal Chemistry. 2024, 102, 117660. (IF3.3).

[9] Jia Yu^#, Xia Wang^#, Sha Cheng, Xiaoping Zeng, Xinwei Wan, Shinan Wei, Bixue Xu, Heng Luo*, Xueling Meng*. Design, synthesis and bioevaluation of novel prenylated chalcones derivatives as potential antitumor agents[J]. European Journal of Pharmaceutical Sciences. 2024, 192, 106660. (IF4.3).

[10] Jia Yu^#, Yunyun Zhou^#, Guangyan Liang, Sha Cheng, Jiaomei Wei, Huimin Li, Xinyu Liu, Chang You, Mengsha Mao, Mashaal Ahmad, Gang Yu, Bixue Xu*, Heng Luo*. Quinazoline derivatives inhibit cell growth of prostate cancer as a WRN helicase dependent manner by regulating DNA damage repair and microsatellite instability [J]. Bioorganic Chemistry. 2024, 153: 107963.(IF5.1).

[11] Mingxiu Chen^#, Sha Cheng^#, Xing Dai, Jia Yu, Huidi Wang, Bixue Xu*, Heng Luo*, Guangcan Xu*. Design, Synthesis, and Biological Evaluation of Novel Quinazoline Derivatives Possessing a Trifluoromethyl Moiety as Potential Antitumor Agents [J]. Chemistry & Biodiversity. 2024, 21(5): e202301776.(IF2.9).

[12] Hui Wu^#, Longshan Wang^#, Pei Li, Jia Yu, Sha Cheng, Gang Yu, Mashaal Ahmad, Xueling Meng, Heng Luo*, Bixue Xu*. Discovery of novel N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as the inhibitors of tubulin polymerization in leukemia cells[J]. European journal of medicinal chemistry, 2023, 256, 115470.(IF7.1).

[13] Kun Liu^#, Min Mo^#, Gang Yu, Jia Yu, Shanmin Song, Sha Cheng, Huimin Li, Xueling Meng, Xiaoping Zeng, Guangcan Xu, Heng Luo*, Bixue Xu*. Discovery of novel 2-(trifluoromethyl)quinolin-4-amine derivatives as potent antitumor agents with microtubule polymerization inhibitory activity[J]. Bioorganic chemistry, 2023, 139, 106727. (IF5.3).

[14] Zhonghang Wen^#, Yongqiang Zhang^#, Xinghui Wang, Xiaoping Zeng, Zhanxing Hu, Yi Liu, Yuxin Xie , Guangyi Liang, Jianguo Zhu*, Heng Luo*, Bixue Xu*. Novel 3′,5′-diprenylated chalcones inhibited the proliferation of cancer cells in vitro by inducing cell apoptosis and arresting cell cycle phase [J]. European Journal of Medicinal Chemistry, 2017, 133, 227-239. (IF4.5).

[15] Hongju Chen, Zhanxing Hu, Jianxin Zhang, Guangyi Liang*, Bixue Xu*. A modified fluoro-Pummerer reaction with DAST and NIS for synthesis of β-amino-α-fluoro-sulfides from corresponding β-amino-sulfides[J]. Tetrahedron, 2015, 71 (14): 2089-2094. (IF2.6).

[16] Luca Unione^#, Bixue Xu^#(共一), Dolores Díaz, Sonsoles Martín-Santamaría, Ana Poveda, João Sardinha, Amelia Pilar Rauter, Yves Blériot, Yongmin Zhang, F. Javier Cañada, Matthieu Sollogoub*, Jesus Jiménez-Barbero*. Conformational Plasticity in Glycomimetics: Fluorocarbamethyl-L-idopyranosides Mimic the Intrinsic Dynamic Behaviour of Natural Idose Rings[J]. chemistry - a european journal, 2015, 21 (29): 10513 – 10521. (IF5.7).

[17] Bixue Xu^#, Ning Wang^#, Weidong Pan, Jingying Qiu, Peixue Cao, Meifen Zhu, Yibin Feng*, Guangyi Liang*. Synthesis and anti-tumor activity evaluation of Matijin-Su derivatives [J]. Bioorganic Chemistry, 2014, 56, 34–40. (IF2.2).

[18] Bixue Xu^#, Luca Unione^#, Joao Sardinha, Shaoping Wu, Mélanie Ethève-Quelquejeu, Amelia Pilar Rauter, Yves Blériot, Yongmin Zhang, Sonsoles Martín-Santamaría, Dolores Díaz, Jesus Jiménez-Barbero*, Matthieu Sollogoub*. gem-Difluorocarbadisaccharides: restoring the exo-anomeric effect[J]. Angewandte Chemie International Edition, 2014, 53(36): 9597-9602. (IF13.6).